Thiogenesis Reports Results of 2026 Annual and Special Meeting of Shareholders and Provides Corporate Update

All items of business put before shareholders at the Meeting were approved by the requisite majority of votes cast. Shareholders elected the following directors to serve until the next annual meeting or until their successors are elected or appointed: Dr. Christopher Starr (Chair), Kim Tsuchimoto (Audit Committee Chair), Hogan Mullally, Dr. Gilad Aharon (Co-Founder and Portfolio Manager, Rosalind Advisors, Inc.), Dr. Patrice Rioux, and Brook Riggins. MNP LLP was also reappointed as the Company's auditor until the next annual meeting or until a successor is appointed. A majority of the disinterested Shareholders also approved an amendment to the Company's 2024 Omnibus Equity Incentive Plan.

Nephropathic cystinosis is a rare genetic disease that prevents the body from properly clearing a toxic amino acid, cystine, out of cells. Left inadequately treated, cystine buildup progressively damages the kidneys and other organs, often leading to kidney failure in childhood. The current standard of care, Procysbi ® , requires patients to swallow, depending on body weight, between 16 and 28 capsules a day, twice daily, on a strict fasting schedule, a pill burden and rigid routine that becomes increasingly difficult to sustain over a lifetime of therapy, with lapses in adherence allowing toxic cystine buildup to resume and cause further organ damage. TTI-0102 is designed to replace that regimen with the potential for a once-daily powder, available in different strengths so dosing can be tailored to each patient's weight, eliminating pills entirely while continuing to clear cystine from cells. The Company plans to initiate an investigator-initiated study of TTI-0102 in patients with nephropathic cystinosis in the fourth quarter of 2026, in collaboration with Dr. Larry Greenbaum at Emory University. The study will enroll approximately 6 adult patients already on standard cysteamine therapy, who will switch to once-daily TTI-0102 for a short treatment period before returning to their regular medication. The primary goal is to confirm that a single daily dose of TTI-0102 can keep cystine levels suppressed over a full 24-hour period, the standard needed to potentially reduce dosing frequency from the current multiple-times-per-day regimen. Topline data from the study are anticipated in the first quarter of 2027.

Leigh syndrome is a rare, severe mitochondrial disease that typically appears in infancy or early childhood, progressively impairing the body's ability to produce cellular energy. There are currently no approved treatments, and care is limited to managing symptoms. TTI-0102 is designed to boost the body's natural antioxidant defenses and reduce the cellular stress associated with the disease. The Company plans to initiate its Phase 2a clinical trial of TTI-0102 in Leigh syndrome in the fourth quarter of 2026, in collaboration with a leading U.S. children's hospital, under an active U.S. FDA Investigational New Drug application. The randomized, placebo-controlled trial will enroll approximately 9 adolescent and adult patients, two-thirds of whom will receive TTI-0102 daily for a 12-week treatment period. The study will measure changes in biomarkers of oxidative stress and cellular energy production, including glutathione, alongside patient-reported measures of fatigue and daily functioning. Topline data are anticipated in the second quarter of 2027.